HIV Research and Development

Lenacapavir has moved long-acting HIV prevention from a trial concept into guideline and regulatory implementation. The research question is now as much about equitable delivery, testing and persistence as biological efficacy.

Injectable and extended-duration antiretroviral platforms aim to reduce dosing burden while maintaining suppression. Current research explores wider populations, longer intervals, oral weekly regimens and combinations with new mechanisms.

Rather than asking one immunogen to produce mature broadly neutralizing antibodies, germline-targeting programmes try to activate rare precursor B cells and guide their maturation through a planned sequence of immunogens.

Broadly neutralizing antibodies can directly block susceptible HIV variants and recruit immune functions. Combinations are designed to widen coverage and reduce escape, with studies testing prevention, treatment support and remission after pausing ART.

Therapeutic vaccines aim to strengthen or redirect immune control in people who already have HIV. The leading strategy is combination treatment rather than vaccination alone.

The ‘shock and kill’ family of strategies tries to expose latent proviruses and then remove infected cells. Research has increasingly shifted toward combination designs because latency reversal alone has not reliably reduced the intact reservoir.

Block-and-lock strategies seek to place persistent HIV into a deeper, durable transcriptionally silent state so that rebound remains suppressed without continuous ART, even if every provirus is not removed.

Gene-editing programmes aim either to cut conserved HIV sequences from infected cells or make target cells resistant to infection. The first challenge is safe delivery to enough relevant cells and tissues.

Cell therapies attempt to provide persistent immune effectors that recognize conserved HIV targets, resist exhaustion or deliver antiviral molecules. Designs include expanded HIV-specific T cells, engineered receptors and NK-cell approaches.

Rare cures after donor stem-cell transplantation prove that durable HIV remission is biologically possible, but transplantation risk makes that route inappropriate for routine HIV care. Research therefore explores safer engineered autologous cells and multilayered resistance.

Cure research depends on measuring a rare, diverse and anatomically distributed reservoir. No single assay captures intactness, inducibility, integration site, clonality, transcription and rebound competence at once.

A scientifically successful intervention has limited public-health value if it cannot reach the populations and regions most affected by HIV. Equity research must begin during product design, not after approval.